# Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

> **NCT02534337** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Guangxi Medical University**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** GEMOX
- **DRUG:** FOLFOX4

## Key facts

- **NCT ID:** NCT02534337
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-09
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** It doesn't meet the requirements of randomized trials
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02534337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02534337, "Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02534337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*